Such sEVs expressing ACE2 might not only play a decoy function against SARS-CoV-2 infection, but also prevent the downregulation of ACE2 on type II alveolar cells, and thus promote recovery in COVID-19 patients with acute respiratory distress syndrome (ARDS). This evidence concerns the gene ACE2 and COVID-19.